Aimmune Therapeutics (AIMT) Trading -2.3% Higher

Shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) traded up 2.3% during mid-day trading on Thursday . The company traded as high as $38.92 and last traded at $36.77. 214,102 shares changed hands during mid-day trading, a decline of 48% from the average session volume of 415,708 shares. The stock had previously closed at $37.62.

A number of analysts recently issued reports on the stock. BidaskClub upgraded shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday. Zacks Investment Research lowered shares of Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, December 6th. Credit Suisse Group lifted their price target on shares of Aimmune Therapeutics from $36.00 to $45.00 and gave the stock an “outperform” rating in a research note on Monday, October 23rd. Roth Capital lifted their price target on shares of Aimmune Therapeutics from $60.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Finally, Wedbush restated an “outperform” rating and issued a $70.00 price target (up previously from $42.00) on shares of Aimmune Therapeutics in a research note on Monday, October 23rd. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. Aimmune Therapeutics presently has an average rating of “Buy” and a consensus price target of $57.25.

The company has a market cap of $1,820.92, a P/E ratio of -15.72 and a beta of -0.82.

Aimmune Therapeutics (NASDAQ:AIMT) last released its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.09. research analysts expect that Aimmune Therapeutics Inc will post -2.51 EPS for the current year.

In other Aimmune Therapeutics news, insider Douglas T. Sheehy sold 1,906 shares of the business’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $38.66, for a total transaction of $73,685.96. Following the completion of the sale, the insider now owns 1,906 shares in the company, valued at $73,685.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Douglas T. Sheehy sold 1,648 shares of the business’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $35.87, for a total transaction of $59,113.76. The disclosure for this sale can be found here. In the last quarter, insiders have sold 134,294 shares of company stock valued at $5,097,144. 24.56% of the stock is owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in AIMT. Legal & General Group Plc increased its stake in Aimmune Therapeutics by 26.6% during the second quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock valued at $160,000 after purchasing an additional 1,634 shares during the last quarter. SG Americas Securities LLC increased its stake in Aimmune Therapeutics by 54.7% during the third quarter. SG Americas Securities LLC now owns 8,430 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 2,979 shares during the last quarter. Daiwa SB Investments Ltd. boosted its holdings in shares of Aimmune Therapeutics by 44.5% during the fourth quarter. Daiwa SB Investments Ltd. now owns 7,290 shares of the biotechnology company’s stock valued at $276,000 after acquiring an additional 2,245 shares during the period. Teacher Retirement System of Texas acquired a new position in shares of Aimmune Therapeutics during the fourth quarter valued at $282,000. Finally, Voya Investment Management LLC boosted its holdings in shares of Aimmune Therapeutics by 31.2% during the second quarter. Voya Investment Management LLC now owns 15,781 shares of the biotechnology company’s stock valued at $324,000 after acquiring an additional 3,757 shares during the period. Hedge funds and other institutional investors own 73.54% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.com-unik.info/2018/02/08/aimmune-therapeutics-aimt-trading-2-3-higher.html.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit